Literature DB >> 17297002

Imaging degeneration of the substantia nigra in Parkinson disease with inversion-recovery MR imaging.

L Minati1, M Grisoli, F Carella, T De Simone, M G Bruzzone, M Savoiardo.   

Abstract

BACKGROUND AND
PURPOSE: Visualizing with MR imaging and obtaining quantitative indexes of degeneration of the substantia nigra in Parkinson disease have been long-sought goals. We investigated the potential role of area and T1 contrast measurements in differentiating patients from controls and their age-related changes.
METHODS: Eight patients with Parkinson disease, 8 age-matched controls, and 8 young controls were imaged. We obtained the pixel-wise difference between 2 sets of inversion-recovery images, acquired parallel to the bicommissural plane, with different inversion times. Pixel-intensity ratios between lateral and medial nigral regions, and nigral area and substantia-nigra/midbrain area ratios were computed.
RESULTS: Compared with that of controls, loss of substantia nigra was evident in patients, its borders taking a smoother and more irregular appearance. Patients were characterized by a lateral-to-medial gradient, due to reduced hypointensity of the lateral portion of the substantia nigra and relative sparing of its medial portion. The visible nigral area was significantly smaller in patients compared with matched controls (P = .04). The substantia nigra/midbrain area ratio enabled considerably better separation (P = .0001). The lateral/medial pixel-intensity ratio was significantly higher in patients compared with matched controls (P = .01) and in young controls compared with age-matched controls (P = .01).
CONCLUSION: Inversion-recovery sequences may provide a convenient way to visualize nigral degeneration. Relative area and pixel-intensity measurements may integrate other techniques (such as diffusion-tensor imaging on nigrostriatal pathways) in the neuroradiologic diagnosis and follow-up of Parkinson disease by quantitatively assessing the degeneration of the substantia nigra.

Entities:  

Mesh:

Year:  2007        PMID: 17297002      PMCID: PMC7977418     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  16 in total

1.  T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content.

Authors:  J Vymazal; A Righini; R A Brooks; M Canesi; C Mariani; M Leonardi; G Pezzoli
Journal:  Radiology       Date:  1999-05       Impact factor: 11.105

2.  Assessment of relative brain iron concentrations using T2-weighted and T2*-weighted MRI at 3 Tesla.

Authors:  R J Ordidge; J M Gorell; J C Deniau; R A Knight; J A Helpern
Journal:  Magn Reson Med       Date:  1994-09       Impact factor: 4.668

Review 3.  The role of radiotracer imaging in Parkinson disease.

Authors:  B Ravina; D Eidelberg; J E Ahlskog; R L Albin; D J Brooks; M Carbon; V Dhawan; A Feigin; S Fahn; M Guttman; K Gwinn-Hardy; H McFarland; R Innis; R G Katz; K Kieburtz; S J Kish; N Lange; J W Langston; K Marek; L Morin; C Moy; D Murphy; W H Oertel; G Oliver; Y Palesch; W Powers; J Seibyl; K D Sethi; C W Shults; P Sheehy; A J Stoessl; R Holloway
Journal:  Neurology       Date:  2005-01-25       Impact factor: 9.910

4.  Parkinson's disease: a novel MRI method for determining structural changes in the substantia nigra.

Authors:  M Hutchinson; U Raff
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-12       Impact factor: 10.154

5.  Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson's disease.

Authors:  Michael F H Schocke; Klaus Seppi; Regina Esterhammer; Christian Kremser; Katherina J Mair; Benedikt V Czermak; Werner Jaschke; Werner Poewe; Gregor K Wenning
Journal:  Neuroimage       Date:  2004-04       Impact factor: 6.556

6.  Early pathological changes in the parkinsonian brain demonstrated by diffusion tensor MRI.

Authors:  K Yoshikawa; Y Nakata; K Yamada; M Nakagawa
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-03       Impact factor: 10.154

Review 7.  [MRI of degenerative extrapyramidal syndromes. Parkinson disease, progressive supranuclear palsy and multiple system atrophy].

Authors:  A Elkeslassy; Y Miaux; N Martin-Duverneuil; E Brunet; D Savin; J Chiras
Journal:  J Neuroradiol       Date:  1996-12       Impact factor: 3.447

8.  Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy.

Authors:  K Seppi; M F H Schocke; R Esterhammer; C Kremser; C Brenneis; J Mueller; S Boesch; W Jaschke; W Poewe; G K Wenning
Journal:  Neurology       Date:  2003-03-25       Impact factor: 9.910

9.  Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease.

Authors:  J M Gorell; R J Ordidge; G G Brown; J C Deniau; N M Buderer; J A Helpern
Journal:  Neurology       Date:  1995-06       Impact factor: 9.910

10.  MRI correlates of pathology in parkinsonism: segmented inversion recovery ratio imaging (SIRRIM).

Authors:  Michael Hutchinson; Ulrich Raff; Sergey Lebedev
Journal:  Neuroimage       Date:  2003-11       Impact factor: 6.556

View more
  23 in total

1.  Substantia nigra in Parkinson's disease: a multimodal MRI comparison between early and advanced stages of the disease.

Authors:  Domenico Aquino; Valeria Contarino; Alberto Albanese; Ludovico Minati; Laura Farina; Marina Grisoli; Luigi Romita; Antonio Emanuele Elia; Antonio Elia; Maria Grazia Bruzzone; Luisa Chiapparini
Journal:  Neurol Sci       Date:  2013-12-11       Impact factor: 3.307

2.  Present and Future of Ultra-High Field MRI in Neurodegenerative Disorders.

Authors:  Graziella Donatelli; Roberto Ceravolo; Daniela Frosini; Michela Tosetti; Ubaldo Bonuccelli; Mirco Cosottini
Journal:  Curr Neurol Neurosci Rep       Date:  2018-04-20       Impact factor: 5.081

3.  Comparison of 3T and 7T susceptibility-weighted angiography of the substantia nigra in diagnosing Parkinson disease.

Authors:  M Cosottini; D Frosini; I Pesaresi; G Donatelli; P Cecchi; M Costagli; L Biagi; R Ceravolo; U Bonuccelli; M Tosetti
Journal:  AJNR Am J Neuroradiol       Date:  2014-11-06       Impact factor: 3.825

Review 4.  Magnetic resonance imaging for the diagnosis of Parkinson's disease.

Authors:  Beatrice Heim; Florian Krismer; Roberto De Marzi; Klaus Seppi
Journal:  J Neural Transm (Vienna)       Date:  2017-04-04       Impact factor: 3.575

5.  New MRI Biomarkers Advance the Characterization of Parkinson Disease.

Authors:  David A Ziegler; Suzanne Corkin
Journal:  Eur Neurol Rev       Date:  2013

Review 6.  Distinguishing Neuroimaging Features in Patients Presenting with Visual Hallucinations.

Authors:  T T Winton-Brown; A Ting; R Mocellin; M Walterfang; D Velakoulis; F Gaillard
Journal:  AJNR Am J Neuroradiol       Date:  2016-01-07       Impact factor: 3.825

Review 7.  A review of the use of magnetic resonance imaging in Parkinson's disease.

Authors:  Nadya Pyatigorskaya; Cécile Gallea; Daniel Garcia-Lorenzo; Marie Vidailhet; Stéphane Lehericy
Journal:  Ther Adv Neurol Disord       Date:  2014-07       Impact factor: 6.570

8.  Degenerative changes were common in brain magnetic resonance imaging in patients with newly diagnosed Parkinson's disease in a population-based cohort.

Authors:  Jan Linder; Richard Birgander; Ingegerd Olsson; Katrine Riklund; Ann-Katrine Larsson; Mona Edström; Hans Stenlund; Lars Forsgren
Journal:  J Neurol       Date:  2009-05-31       Impact factor: 4.849

9.  Patch-based label fusion segmentation of brainstem structures with dual-contrast MRI for Parkinson's disease.

Authors:  Yiming Xiao; Vladimir S Fonov; Silvain Beriault; Ian Gerard; Abbas F Sadikot; G Bruce Pike; D Louis Collins
Journal:  Int J Comput Assist Radiol Surg       Date:  2014-09-24       Impact factor: 2.924

10.  Pool size ratio of the substantia nigra in Parkinson's disease derived from two different quantitative magnetization transfer approaches.

Authors:  Paula Trujillo; Paul E Summers; Alex K Smith; Seth A Smith; Luca T Mainardi; Sergio Cerutti; Daniel O Claassen; Antonella Costa
Journal:  Neuroradiology       Date:  2017-10-06       Impact factor: 2.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.